Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9652W HIGH $3.95
Volume
1.64 K
Value Traded
185.59 K
Short % Float
4.27%
-0.97%Week
-14.29%1 Month
-22.73%3 Month
-28.67%6 Month
-86.83%5 Year
-86.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
37.85 M
EPS (TTM)
-2.47
P/E Ratio
-
Ent. Value
-82.13 M
Total Shares
37.78 M
Float Shares
29.82 M
Insiders
21.07%
Institutions
16.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MGX Catalyst Timeline
Dated clinical, regulatory and corporate events for Metagenomi Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Metagenomi Therapeutics, Inc.
108Total events
3Upcoming
4Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPresentation
Metagenomi to present at Jefferies Global Healthcare Conference
▲PublicationMG119Presentation
Publication in Nature Structural & Molecular Biology on MG119-28
▲PublicationMG119Presentation
Publication in Nature Structural & Molecular Biology on MG119-28
▲Preclinical PoCMGX-001Preclinical
Preclinical data demonstrating curative FVIII activity in NHPs
Hemophilia Asource ↗
▲Preclinical PoCPreclinical
In vivo proof-of-concept in NHPs for AT-III Deficiency
Antithrombin (AT-III) Deficiencysource ↗
●Oral PresentationPresentation
Presented preclinical data on APOC3 at Nature Conference
Cardiometabolicsource ↗
◆Oral PresentationPresentation
Presentation of preclinical data for APOC3 collaboration target at Nature Conference
Severe Hypertriglyceridemiasource ↗
◆Oral PresentationPresentation
Metagenomi to present at Jefferies Global Healthcare Conference in London
▲Preclinical PoCMGX-001Preclinical
New preclinical data demonstrating curative FVIII activity in NHPs
hemophilia Asource ↗
◆Management ChangeCorporate
Jian Irish appointed CEO; Brian Thomas remains on Board; Willard Dere appointed Board Chair
●Oral PresentationMGX-001Presentation
Conference call to discuss MGX-001 preclinical results and business updates
hemophilia Asource ↗
◆Pre IND MeetingMGX-001FDA Meeting
Pre-IND meeting for MGX-001 expected in Q4 2025
hemophilia Asource ↗
●Quarterly UpdateCorporate
Reported Q2 2025 financial results and cash position of $205.0 million
◆Oral PresentationPresentation
Oral presentation at TIDES USA 2025: AI-Guided Metagenomic Discovery of Compact CRISPR Systems for In Vivo Therapeutic Genome Editing
◆Poster PresentationPresentation
Poster presentation at ASGCT 2025: Site-Specific Integration of Therapeutic Transgenes with a Type V-K CAST System Engineered for Efficient and Targeted Human Genome Editing
▲Full ResultsMGX-001Clinical Data
NHP study durability results at approximately 19 months
hemophilia Asource ↗
▲Oral PresentationPresentation
Presented three abstracts at ASGCT demonstrating early proof-of-concept data across multiple gene editing technologies
▲PublicationPresentation
Publication in Nature Communications on compact CAST system for large gene integration
◆Oral PresentationPresentation
Metagenomi CEO to present at TD Cowen's 45th Annual Health Care Conference
◆Oral PresentationPresentation
Metagenomi presentation at 43rd Annual J.P. Morgan Healthcare Conference
▲Oral PresentationMG119Presentation
ASGCT 2025 presentation of in vivo proof of concept for MG119-28
◆Pre IND MeetingMGX-001FDA Meeting
Pre-IND and ex-U.S. regulatory meetings for MGX-001 in 2025
Hemophilia Asource ↗
◆Development Candidate NominationPreclinical
Nomination of development candidates for Ionis collaboration in cardiometabolic indications in 2025
Cardiometabolic indicationssource ↗
◆Timing GuidancePresentation
Additional updates on further advancements in novel large gene integration technology anticipated in 2025
▲Preclinical PoCMGX-001Preclinical
MGX-001 demonstrated curative FVIII activity in NHPs
hemophilia Asource ↗
●Preclinical PoCPreclinical
NHP proof-of-concept for lead secreted protein deficiency target
Secreted protein deficienciessource ↗
●Oral PresentationPresentation
Preclinical data on APOC3 presented at Nature Conference
cardiometabolicsource ↗
◆IND Enabling CompletePreclinical
Plan to initiate IND-enabling activities for DCs nominated in 2025
cardiometabolic indicationssource ↗
◆Oral PresentationPresentation
Presentation at Nature Conference: RNA at the Bench and Bedside IV
◆Oral PresentationMGX-001Presentation
Oral presentation of preclinical data for MGX-001 at ASH 2024
Hemophilia Asource ↗
◆Oral PresentationPresentation
Piper Sandler 36th Annual Healthcare Conference (1x1 meetings)
▲Oral PresentationMGX-001Presentation
Oral presentation at ASH 2024: Site-Specific Insertion of Factor VIII Gene Results in Durable Factor VIII Expression in Nonhuman Primates
Hemophilia Asource ↗
Past FDA Catalysts and PDUFA Decisions
How MGX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-11 | MGX-001 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every MGX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MGX-001 | hemophilia A | 2024-12-09 | FVIII activity months 13 16: 71, 7, 27; FVIII activity months 3 6: 76, 8, 30; FVIII activity months 7 12: 77, 8, 32; FVIII levels at 16 5 months: 72, 9, 30; gene integration frequency: 0.7, 1.3, 3.1Read More | Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Reid LaurenceDirector | Buy | 117 20,000 held | $1.18 | 09/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MGX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 % | 66.00 K | 28.01 K | -86% ( -171.99 K) |
MGX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MGX ranks across every disease it competes in
Competitive Position is a premium feature
See how MGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMGX News
MGX▼ -1.8%today
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
Metagenomi Therapeutics, Inc. will participate in the Chardan 10th Annual Healthcare Conference, where CEO Jian Irish will discuss advancements in genome editing. The event is scheduled for October 20, 2026, in New York City. The company aims to leverage its proprietary technologies to develop curative genetic medicines, focusing on hemophilia A and other disease indications.
Read more →MGXMetagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Metagenomi Therapeutics, Inc. will present at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. CEO Jian Irish will participate in a fireside chat, discussing the company's proprietary genome editing technologies and its lead program, MGX-001, aimed at treating hemophilia A. The event will be available for viewing on the company's website.
Read more →MGXMetagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Metagenomi Therapeutics is progressing towards submitting an investigational new drug application for MGX-001, aimed at treating hemophilia A, expected in the fourth quarter of 2026. The company reported having $120.7 million in cash and equivalents as of June 30, 2026, ensuring a solid financial runway for its upcoming clinical endeavors.
Read more →MGXMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
Metagenomi Therapeutics, Inc. announced that CEO Jian Irish will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The company focuses on developing curative genetic medicines using its proprietary genome editing technologies. Its lead program, MGX-001, aims to provide a one-time treatment for hemophilia A, potentially setting a new standard of care.
Read more →MGXMetagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Metagenomi Therapeutics has reported its business updates and first-quarter financial results for 2026. The company is on schedule for the regulatory submission of its MGX-001 program aimed at treating hemophilia A, with plans to initiate clinical trials in 2027. A recent publication in Nature has showcased the promising capabilities of their proprietary MG119-28 CRISPR nuclease. Metagenomi currently has a strong cash reserve of $140.2 million, which is projected to sustain its operations until at least late 2027.
Read more →MGXMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Metagenomi Therapeutics, Inc. announced a publication in Nature Structural & Molecular Biology detailing the compact CRISPR nuclease MG119-28, which exhibits enhanced genome editing efficiency. The study reveals that MG119-28's superior structural stability and stable guide RNA contribute to its effectiveness. The company aims to leverage these findings to advance gene editing applications beyond liver-related diseases.
Read more →MGXMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Metagenomi Therapeutics, Inc. (MGX) announced significant advancements in its pipeline, including the completion of a pre-IND meeting for their MGX-001 hemophilia A program, supporting potential clinical trials in 2027. The company reported a solid financial position with $160.8 million in cash, indicating a runway through 2027. A corporate name change was also announced, aligning with the firm’s strategic evolution in the genetic medicine space. The preclinical data demonstrated curative FVIII activity in non-human primates, which positions MGX-001 as a competitive treatment option.
Read more →MGX▲ +6.4%on this news
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
Metagenomi Therapeutics, Inc. announced its participation in the 46th Annual TD Cowen Healthcare Conference, where CEO Jian Irish will discuss the company's advancements. The focus will be on their lead program, MGX-001, which aims to provide a curative treatment for hemophilia A. The company is leveraging its proprietary technologies to expand its pipeline of genetic medicines.
Read more →MGXMetagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
Metagenomi Therapeutics, Inc. has announced its corporate name change to reflect its focus on advanced gene-editing technologies. The company highlighted significant milestones achieved in 2025, particularly with its lead program MGX-001 for hemophilia A, which demonstrated promising preclinical results. Anticipated IND/CTA submissions are planned for late 2026, with a cash runway expected to last through 2027.
Read more →MGX▼ -8.6%on this news
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
Metagenomi, Inc. announced it will present preclinical data on APOC3 at the upcoming Nature Conference. This collaboration with Ionis Pharmaceuticals focuses on a CRISPR/Cas-mediated approach to treat severe hypertriglyceridemia. The presentation will be delivered by Alan Brooks, PhD, on December 8, 2025, in Boston, MA.
Read more →MGXMetagenomi to Present at Jefferies Global Healthcare Conference in London
Metagenomi, Inc. announced that its CEO, Jian Irish, will present at the Jefferies Global Healthcare Conference in London on November 20, 2025. The company focuses on in vivo genome editing and has developed proprietary technologies aimed at creating curative genetic medicines. MGX-001, their lead program targeting hemophilia A, has demonstrated promising preclinical results. Metagenomi is also exploring other indications, highlighting its commitment to expanding its product pipeline.
Read more →MGX▼ -15.5%on this newsshared move
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
Metagenomi reported its third quarter 2025 financial results, highlighting positive preclinical data for its MGX-001 hemophilia A program. The company is prioritizing its later-stage preclinical pipeline and has undergone a workforce reduction of 25% to optimize operations. Jian Irish has been appointed as the new CEO, succeeding Brian Thomas, who will remain on the Board.
Read more →MGX▼ -15.5%on this newsshared move
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
Metagenomi has reported promising preclinical data for its MGX-001 hemophilia A program, demonstrating curative FVIII activity in non-human primates. The company plans to advance MGX-001 into clinical development, with regulatory submissions expected by the end of 2026. This approach aims to provide a one-time treatment that restores the body's ability to produce FVIII.
Read more →MGXMetagenomi Reports Business Updates and Second Quarter 2025 Financial Results
Metagenomi, Inc. reported its financial results for Q2 2025, highlighting a robust cash position of $205 million, which is expected to support operations until 2027. The company is advancing its MGX-001 program for hemophilia A and collaborating with Ionis on cardiometabolic indications. Additionally, Metagenomi presented three abstracts at the ASGCT, showcasing its gene editing technologies.
Read more →MGXMetagenomi Appoints Laurence Reid, PhD to its Board of Directors
Metagenomi, Inc. has appointed Laurence Reid, PhD, to its Board of Directors, enhancing its leadership team. Dr. Reid brings extensive experience in biotech and business development, which is expected to support the company's growth and innovation in gene editing technologies. His appointment comes at a crucial time as Metagenomi aims to advance its therapeutic pipeline.
Read more →MGX▼ -6.2%on this news
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
Metagenomi presented significant advancements in genome editing technologies at the ASGCT Annual Meeting 2025. The company showcased its capabilities in extrahepatic gene editing and site-specific integration of large therapeutic genes. These innovations aim to improve treatment options for neurological disorders and other diseases caused by genetic mutations.
Read more →MGXMetagenomi Reports Business Updates and First Quarter 2025 Financial Results
Metagenomi, Inc. has reported robust financial results for the first quarter of 2025, showcasing impressive durability of factor VIII activity in their hemophilia A program during a nonhuman primate study. The study reported sustained therapeutic levels of FVIII activity lasting approximately 19 months, with no major safety concerns. The company remains well-funded, having $226 million available, which is projected to support operations through 2027. Advances in their gene editing technologies are underscored by a recent publication in Nature Communications regarding their metagenomics platform.
Read more →MGX▲ +8.1%on this news
Metagenomi to Present at Upcoming Scientific Meetings
Metagenomi, Inc. announced its participation in two upcoming scientific meetings, including an oral presentation at TIDES USA 2025 and three poster presentations at the ASGCT 2025 Annual Meeting. The presentations will focus on advanced gene editing technologies and their applications in therapeutic settings. This highlights Metagenomi's commitment to innovation in precision genetic medicine.
Read more →MGXMetagenomi Reports Business Updates and Full Year 2024 Financial Results
Metagenomi, a precision genetic medicines company, has released its full year 2024 financial results and business updates. Significant achievements include demonstrating sustained Factor VIII activity for over 16 months in nonhuman primate studies and advancing their MGX-001 program for hemophilia A. The company has made progress in collaboration with Ionis Pharmaceuticals, with plans to nominate development candidates in 2025. Additionally, Metagenomi remains well-capitalized with over $248 million in cash to support its future operations.
Read more →About Metagenomi Therapeutics, Inc.
Headquarters5959 HORTON STREET, EMERYVILLE, CA, 94608
BIOPHARMAWATCH ELITE PLUS
Trade the next MGX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime